Antares Pharma, Inc. (ATRS)

[rdfdr1]

re: Libigel. I don't know if this is new to anyone but I just found it and I read it as a right reserved to ATRS to cancel ANIP/BPAX's rights to Libigel upon failure to pursue FDA's approval. This is taken from a BPAX filing with the SEC.
Re: BioSante Pharmaceuticals, Inc.
Form 10-K for the fiscal year ended December 31, 2011
Filed March 13, 2012
File No. 001-31812

"The term of our license agreement with Antares will expire on a country-by-country and product-by-product basis when the royalties expire (at patent expiration), at which time we will have a fully paid-up exclusive license regarding the applicable product in such country. We and Antares may terminate the license agreement upon the occurrence of certain events, including a material breach of the agreement by the other party or if the other party goes into liquidation or bankruptcy or makes an assignment for the benefit of creditors or a receiver is appointed. Antares may terminate the agreement with respect to certain products or territories if we do not continue development, seeking regulatory approval or marketing of such products in the covered territories. We may terminate the agreement with respect to certain products or territories if, for technical, scientific or regulatory reasons, it is not likely that the product will gain required regulatory approvals in a territory, if regulatory approvals in a territory are not obtained or if we determine that it is not economically viable to continue development or marketing of a product in a territory.”